The case for & against
Bull & Bear analysis
Bearish
Surrozen Inc. (NASDAQ:SRZN) is a biotechnology company in the development stage focused on innovative therapeutics targeting the Wnt signaling pathway to promote tissue repair and regeneration. The company operates at the intersection of regenerative medicine, addressing critical unmet medical needs through proprietary antibody engineering techniques. Surrozen’s key pipeline candidates, SCN043 and SCN1326, specifically target conditions like severe alcoholic hepatitis and inflammatory bowel disease, positioning the company within the expanding market of regenerative therapies.
Bull says
- ↑SCN043 and SCN1326 target severe alcoholic hepatitis and IBD
- ↑Phase 1B trials launch in 2024 with data expected H2 2024
- ↑Strong growth factor and positive momentum signal rising investor interest
- ↑High 13F ownership reflects robust institutional backing
- ↑Boehringer collaboration could yield $10 M in milestone payments
- ↑$76 M cash reserves fund operations into H2 2024
Bear says
- ↓Zero revenue reported; Q1 2026 EPS of –$11.65 vs –$1.11 est.
- ↓Deeply negative profitability score and unfavorable earnings yield
- ↓High leverage score limits financial flexibility
- ↓Negative analyst revisions point to weakening outlook
- ↓Adverse events in trials may delay regulatory approvals
- ↓Rising interest rates heighten debt-service and refinancing risks
Earnings Call · Q4 2022 · Mgmt. Guidance
Updated 07-04-2026neutral
Transcript signals
Bull points
- We believe that the Wnt pathway's broad physiologic role portends a role for Wnt therapeutics in a wide range of severe and acute diseases.
- We're currently focused on two key clinical areas: severe alcoholic hepatitis with our candidate SCN043, and inflammatory bowel disease with our candidate SCN1326.
- We believe this broad physiologic role portends a role for Wnt therapeutics in a wide range of severe and acute diseases.
Bear points
- In November, we disclosed several adverse events observed in clinical trials that had commenced in 2022, and one of the studies, the phase one single ascending dose study for SCN1326, was voluntarily paused pending further evaluation of grade three transaminase or liver enzyme elevations.
- And 30% die within 90 days due to hepatocyte loss and lack of sufficient regeneration to overcome that loss.
- Although the protocol did not require that we halt the study, we announced a voluntary pause to enrollment in the phase one healthy volunteer portion of the study in November following an observation of a grade three ALT elevation at a lower dose in order to give us an opportunity to analyze the clinical data.
Read full transcript analysis ›